Driving Naari Programme launched in Chandigarh
The World Health Organisation on Tuesday said a decision on the Emergency Use Listing (EUL) of India’s home-grown coronavirus vaccine, Covaxin, will be finalised next week when the health watchdog and an independent group of experts will meet to carry out an assessment of the risks and benefits of the jab.
In a tweet, WHO said: ‘WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin.’
WHO further wrote that Hyderabad-based Bharat Biotech, which manufactured Covaxin, had submitted additional information at the request of the health body on September 27, which is being currently reviewed.
‘Covaxin manufacturer, Bharat Biotech, has been submitting data to WHO on a rolling basis and submitted additional info at WHO’s request on 27 September. WHO experts are currently reviewing this info and if it addresses all questions raised, WHO assessment will be finalised next week,’ it said.
WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin.#COVID19pic.twitter.com/jJyS1hiz44
— World Health Organization (WHO) (@WHO) October 5, 2021
